3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.1%) at 18,080 as of Tuesday, May 12, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,119 issues advancing vs. 1,860 declining with 154 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Opko Health ( OPK), up 3.1%, Sanofi ( SNY), up 1.0% and Gilead ( GILD), up 0.7%. On the negative front, top decliners within the industry include NewLink Genetics ( NLNK), down 28.1%, DepoMed ( DEPO), down 18.1%, Endo International ( ENDP), down 2.8%, Mylan ( MYL), down 1.6% and AstraZeneca ( AZN), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Dr Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Dr Reddy Laboratories is up $1.25 (2.4%) to $54.26 on heavy volume. Thus far, 224,176 shares of Dr Reddy Laboratories exchanged hands as compared to its average daily volume of 298,800 shares. The stock has ranged in price between $53.14-$54.36 after having opened the day at $53.55 as compared to the previous trading day's close of $53.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr Reddy Laboratories has a market cap of $9.0 billion and is part of the health care sector. Shares are up 5.1% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dr Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Dr Reddy Laboratories Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY